%PDF-1.3
%‚„œ”
1 0 obj
<<
/Type/ExtGState
/OPM 1
>>
endobj
2 0 obj
<<
/SM 0.01
/Type/ExtGState
/FL 1
>>
endobj
3 0 obj
<<
/OP true
/Type/ExtGState
>>
endobj
4 0 obj
<<
/OP false
/Type/ExtGState
>>
endobj
5 0 obj
<<
/Length 7521
>>
stream
/GS0 gs
q
0 0.157 501 700 re
W n
1 g
0 700.157 0 0 re
f
Q
/GS1 gs
/GS2 gs
q
0 J 0 j 10 M []0 d 0.3 w 
0 0 0 1 K
14.173 668.976 m
487.559 668.976 l
S
Q
/GS3 gs
/GS2 gs
q
BT
/F0 1 Tf
9 0 0 9 14.1732 672.0087 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
(ARCH SOC ESP OFTALMOL 2007; 82: 765-768)Tj
ET
0 0 0 0 k
14.173 537.3619 473.386 111.771 re
f
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
17 0 0 17 67.6508 637.5247 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
[(OFT)90(ALMOP)74(A)95(T\352A DISTIR)29(OIDEA ASOCIAD)35(A A)]TJ
6.36795 -1.05882 TD
0 Tw
[(HIPO)40(TIR)29(OIDISMO)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
15 0 0 15 49.6859 587.5247 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
[(D)40(YSTHYR)30(OID OPHTHALMOP)73(A)95(THY ASSOCIA)95(TED WITH)]TJ
8.66959 -1.06667 TD
0 Tw
[(HYPO)40(THYR)29(OIDISM)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 138.3159 543.5247 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
[(MA)40(CI\347-BOBES C)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
8.25 0 0 8.25 224.0074 547.1548 Tm
0 Tr
0 0 0 1 k
0 Tc
(1)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 228.1324 543.5247 Tm
0 Tr
0 0 0 1 k
0 Tc
(,)Tj
0.52499 0 Td
0.025 Tw
[(R)40(ONZ\356N-FERN\347NDEZ A)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
8.25 0 0 8.25 359.2914 547.1548 Tm
0 Tr
0 0 0 1 k
0 Tc
(2)Tj
ET
0 0 0 0 k
14.173 31.181 473.386 127.141 re
f
0 J 0 j 10 M []0 d 0.5 w 
0 0 0 1 K
14.173 142.086 m
133.228 142.086 l
S
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
8 0 0 8 14.1732 131.9149 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
[(Recibido:)-250(17/5/06. Aceptado: 30/10/07.)]TJ
0 -1.12499 TD
(Secci\227n de Endocrinolog\222a. Departamento de Medicina Interna. Hospital San Agust\222n. Avil\216s. Asturias. Espa\226a.)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
6 0 0 6 14.1732 116.555 Tm
0 Tr
0 0 0 1 k
0 Tc
(1)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
8 0 0 8 21.1732 113.915 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
(Doctora en Medicina. )Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
6 0 0 6 14.1732 107.555 Tm
0 Tr
0 0 0 1 k
0 Tc
(2)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
8 0 0 8 21.1732 104.915 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
(Licenciada en Medicina. )Tj
-0.875 -2.25 TD
0 Tw
(Correspondencia:)Tj
0 -1.125 TD
0.025 Tw
(Carmen Maci\207 Bobes)Tj
T*
(Secci\227n de Endocrinolog\222a. Hospital San Agust\222n)Tj
T*
(Camino de Heros, 4)Tj
T*
(33400 Avil\216s (Asturias))Tj
T*
0 Tw
(Espa\226a)Tj
T*
0.025 Tw
(E-mail: cmacb@arrakis.es)Tj
ET
0 0 0 0 k
14.173 197.8 226.772 312.857 re
f
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
13 0 0 13 95.0622 501.7798 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(RESUMEN)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
11 0 0 11 14.1732 477.4798 Tm
0 Tr
0 0 0 1 k
0 Tc
0.132 Tw
(Caso cl\222nico:)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 80.0027 477.4798 Tm
0 Tr
0 0 0 1 k
0 Tc
0.132 Tw
(La oftalmopat\222a por enfermedad de)Tj
-5.9845 -1.10454 TD
0.094 Tw
[(Gra)20(v)14(es \(e)15(xoftalmos, inf)20(iltraci\227n muscular y palpe-)]TJ
0 -1.10455 TD
0.16 Tw
(bral\) se asocia casi sistem\207ticamente a hipertiroi-)Tj
T*
0 Tw
(dismo.)Tj
0 -1.10454 TD
(P)Tj
0.54102 0 TD
0.104 Tw
(aciente diagnosticada de hipotiroidismo subcl\222ni)Tj
19.74182 0.00001 TD
(-)Tj
-20.28284 -1.10455 TD
0.01 Tw
(co y tratada adecuadamente con tiroxina oral. Unos)Tj
0 -1.10454 TD
0.06 Tw
[(meses despu\216s desarrolla un e)15(xoftalmos bilateral y)]TJ
0 -1.10455 TD
0.073 Tw
(simult\207neamente presenta anticuerpos s\216ricos anti-)Tj
0 -1.10454 TD
0.008 Tw
(receptor de TSH positi)Tj
9.07905 0 TD
(v)Tj
0.48023 0 TD
(os. Se suspende entonces el)Tj
-9.55928 -1.10455 TD
0.224 Tw
(tratamiento con tiroxina, y se comprueba que el)Tj
T*
0.075 Tw
(hipotiroidismo ha progresado hasta hacerse prima-)Tj
T*
0.129 Tw
(rio. Se establece el diagn\227stico de enfermedad de)Tj
T*
0.025 Tw
[(Gra)20(v)14(es hipotiroidea.)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
11 0 0 11 14.1732 319.5299 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(Discusi\227n:)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 66.7626 319.5299 Tm
0 Tr
0 0 0 1 k
0 Tc
0.087 Tw
(El diagn\227stico se bas\227 en la e)Tj
12.28079 0.00001 TD
0 Tw
(xistencia)Tj
-17.06165 -1.10455 TD
0.001 Tc
0.374 Tw
[(de la oftalmopat\222a y los anticuerpos positi)25(v)19(os,)]TJ
0 -1.10454 TD
0 Tc
0.058 Tw
[(ambos espec\222f)20(icos de la enfermedad de Gra)19(v)15(es. La)]TJ
T*
-0.003 Tw
[(coe)15(xistencia de hipotiroidismo es e)15(xcepcional, pero)]TJ
0 -1.10455 TD
0 Tw
(posible.)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
11 0 0 11 14.1732 246.6299 Tm
0 Tr
0 0 0 1 k
0 Tc
0.173 Tw
[(P)10(alabras cla)25(v)10(e:)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 92.0165 246.6299 Tm
0 Tr
0 0 0 1 k
0 Tc
0.173 Tw
(Oftalmopat\222a por enfermedad de)Tj
-7.07666 -1.10454 TD
0.321 Tw
[(Gra)20(v)14(es, hipotiroidismo, anticuerpos anti-receptor)]TJ
0 -1.10455 TD
0.025 Tw
(de tirotropina, tiroxina, terap\216utica.)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
9.6 0 0 12 372.053 671.8343 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
[(COMUNICA)55(CI\356N COR)40(T)89(A)]TJ
ET
0 0 0 0 k
260.787 197.8 226.772 312.857 re
f
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
13 0 0 13 339.1405 501.7798 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
[(ABSTRA)55(CT)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
11 0 0 11 260.7874 477.4798 Tm
0 Tr
0 0 0 1 k
0 Tc
-0.011 Tw
(Clinical case:)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 325.9099 477.4798 Tm
0 Tr
0 0 0 1 k
0 Tc
-0.011 Tw
[(Gra)20(v)14(es\253 ophthalmopath)5(y \(e)15(xophthal-)]TJ
-5.92023 -1.10454 TD
0.049 Tw
[(mos, muscular and e)15(yelid inf)19(iltration\) is associated)]TJ
0 -1.10455 TD
0.025 Tw
[(almost systematically to h)5(yperth)5(yroidism.)]TJ
-0.0001 Tc
(A)'
1.17907 0 Td
0 Tc
0.207 Tw
[(female patient w)10(as diagnosed with subclinical)]TJ
-1.17907 -1.10454 TD
(h)Tj
0.49512 0 TD
0 Tw
(ypoth)Tj
2.27295 0.00001 TD
0.294 Tw
(yroidism and treated with oral th)Tj
14.54309 0 TD
0 Tw
(yroxine.)Tj
-17.31116 -1.10455 TD
0.052 Tw
(Months later she de)Tj
7.98986 0 TD
[(v)15(eloped bilateral e)15(xophthalmos)]TJ
-7.98986 -1.10454 TD
0.308 Tw
[(and w)10(as serum-positi)24(v)15(e for th)5(yrotropin receptor)]TJ
0 -1.10455 TD
0.34 Tw
[(antibodies. Th)5(yroxine treatment w)9(as suspended,)]TJ
0 -1.10454 TD
-0.009 Tw
(and it w)Tj
3.19418 0 TD
(as v)Tj
1.55913 0.00001 TD
[(erif)20(ied that her condition had de)24(v)15(eloped)]TJ
-4.75331 -1.10455 TD
0.11 Tw
[(into primary h)5(ypoth)5(yroidism. A diagnosis of Gra-)]TJ
T*
0.025 Tw
[(v)15(es\325 disease with h)5(ypoth)5(yroidism w)9(as made.)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
11 0 0 11 260.7874 343.8299 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(Discussion:)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 317.8436 343.8299 Tm
0 Tr
0 0 0 1 k
0 Tc
0.104 Tw
[(The diagnosis w)10(as based on the e)15(xis)-1(-)]TJ
-5.18693 -1.10455 TD
-0.028 Tw
[(tence of ophthalmopath)5(y and positi)25(v)15(e serum antibo)-1(-)]TJ
0 -1.10454 TD
0.224 Tw
(dies, both specif)Tj
6.95446 0.00001 TD
[(ic indicators of Gra)20(v)15(es\325 disease.)]TJ
-6.95446 -1.10455 TD
0.22 Tw
[(The coe)15(xistence of h)5(ypoth)4(yroidism with Gra)20(v)15(es\325)]TJ
0 -1.10454 TD
0.109 Tw
[(disease is e)15(xceptional, b)19(ut possible )]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F0 1 Tf
11 0 0 11 422.8075 295.2299 Tm
0 Tr
0 0 0 1 k
0 Tc
0.109 Tw
[(\(Ar)37(c)15(h Soc Esp)]TJ
-14.7291 -1.10454 TD
0.025 Tw
(Oftalmol 2007; 82: 765-768\).)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
11 0 0 11 260.7874 258.7799 Tm
0 Tr
0 0 0 1 k
0 Tc
0.116 Tw
[(K)25(ey w)10(ords:)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 319.7801 258.7799 Tm
0 Tr
0 0 0 1 k
0 Tc
0.116 Tw
[(Gra)20(v)14(es\253 ophthalmopath)5(y)65(, h)5(ypoth)5(yroi-)]TJ
-5.36297 -1.10454 TD
0.304 Tw
[(dism, th)5(yrotropin receptor antibodies, th)5(yroxine,)]TJ
T*
0 Tw
(therapeutics.)Tj
ET
Q

endstream
endobj
6 0 obj
<<
/Length 9327
>>
stream
/GS0 gs
q
0 0.157 501 700 re
W n
1 g
0 700.157 0 0 re
f
Q
/GS1 gs
q
/GS2 gs
0 0 0 0 k
14.173 29.763 473.386 619.3699 re
f
Q
/GS2 gs
q
BT
/F1 1 Tf
13 0 0 13 75.4019 640.2562 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
[(INTR)30(ODUCCI\356N)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 24.9266 615.9562 Tm
0 Tr
0 0 0 1 k
0.0099 Tc
(La)Tj
1.30128 0 Td
0.01 Tc
-0.033 Tw
[(oftalmopat\222a por enfermedad de Gra)20(v)14(es (EG))]TJ
-2.27886 -1.10454 TD
0.116 Tw
[(se caracteriza por un grado v)25(ariable de proptosis)]TJ
T*
0.118 Tw
[(ocular)40(, generalmente bilateral, y signos inf)19(iltrati-)]TJ
T*
0.091 Tw
[(v)20(os de la musculatura e)15(xtr\222nseca del ojo o de los)]TJ
T*
0.047 Tw
(tejidos blandos periorbitarios. Las formas cl\222nica-)Tj
0 -1.10455 TD
0.248 Tw
[(mente e)25(videntes, que cursar\222an con e)14(xoftalmos,)]TJ
T*
0.081 Tw
(quemosis, edemas palpebrales u oftalmoplejia, se)Tj
T*
0.045 Tw
(presentan en un 10-20% de los pacientes con EG,)Tj
T*
0.237 Tw
(aunque las formas sutiles, demostrables en una)Tj
0 -1.10453 TD
0.099 Tw
(tomograf\222a axial computarizada por ejemplo, son)Tj
0 -1.10455 TD
0.079 Tw
[(mucho m\207s pre)25(v)25(alentes (1). De modo infrecuente)]TJ
T*
0.158 Tw
(esta oftalmopat\222a puede aparecer en ausencia de)Tj
T*
0.372 Tw
(hipertiroidismo, bien asociada a normofunci\227n)Tj
T*
0.291 Tw
[(tiroidea o \321e)15(xcepcionalmente\321 a hipofunci\227n)]TJ
T*
0.069 Tw
((2). Presentamos un caso de EG con hipotiroidis-)Tj
T*
0.025 Tw
[(mo y e)15(xoftalmos. )]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
13 0 0 13 79.1924 397.5563 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
(CASO CL\352NICO)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 24.9266 373.2563 Tm
0 Tr
0 0 0 1 k
0.005 Tc
0.109 Tw
(Mujer de 59 a\226os, sana, no fumadora y asinto-)Tj
-0.97758 -1.10454 TD
0.007 Tw
(m\207tica, remitida desde Atenci\227n Primaria a la con-)Tj
0 -1.10455 TD
0.26 Tw
(sulta de Endocrinolog\222a en agosto de 2003 por)Tj
0 -1.10454 TD
0.133 Tw
(hipotiroidismo subcl\222nico. No presentaba bocio y)Tj
0.0049 Tc
(dos)'
1.77451 0 Td
0.005 Tc
0.116 Tw
(determinaciones recientes de funci\227n tiroidea)Tj
-1.77451 -1.10454 TD
0.01 Tc
0.137 Tw
[(h)5(a)5(b)5<92>5(a)5(n)-392(mostrado ni)24(v)15(eles s\216ricos de tiroxina libre)]TJ
T*
0 Tc
0.035 Tw
[(\()-10(T)-10(4)-10(L)-10(\))-10( )-10(normales y ni)25(v)15(eles de tirotropina (TSH) ele)-1(-)]TJ
0 -1.10453 TD
0.121 Tw
[(v)25(ados: 13,55 y 13,86 mcUI/mL \(v)25(alores normales)]TJ
0 -1.10455 TD
0.01 Tc
0.063 Tw
[<D1>10(V)10(N)10<D1>10(:)-313(0,25-4,22\). Los anticuerpos anti-peroxi-)]TJ
T*
0.085 Tw
[(dasa tiroidea (Ac anti-TPO) eran positi)25(v)19(os a t\222tu-)]TJ
T*
0.253 Tw
(los altos. Con el diagn\227stico de hipotiroidismo)Tj
0 -1.10454 TD
0.039 Tw
(subcl\222nico autoinmunitario sin bocio se inici\227 tra)Tj
20.28285 0 TD
0 Tc
(-)Tj
-20.28285 -1.10455 TD
0.016 Tc
0.369 Tw
(tamiento con 50 mcg/d\222a de tiroxina oral \(1)Tj
0 -1.10454 TD
0.01 Tc
0.093 Tw
(mcg/kg peso\), y se comprob\227 en an\207lisis realiza)Tj
20.28285 0 TD
0 Tc
(-)Tj
-20.28285 -1.10455 TD
0.01 Tc
0.091 Tw
(dos a los 6 y 12 meses que esta dosis de sustitu)Tj
20.28287 0.00001 TD
0 Tc
(-)Tj
-20.28287 -1.10455 TD
0.01 Tc
0.079 Tw
(ci\227n era correcta (TSH normal). En diciembre de)Tj
T*
-0.023 Tw
(2004 la paciente acudi\227 espont\207neamente a la con)Tj
20.28284 0.00001 TD
0 Tc
(-)Tj
-20.28284 -1.10456 TD
0.01 Tc
0.168 Tw
(sulta para comentar que en el \234ltimo mes hab\222a)Tj
0 -1.10454 TD
0.195 Tw
(notado protrusi\227n de los globos oculares, irrita-)Tj
0 -1.10455 TD
-0.009 Tw
(ci\227n conjunti)Tj
5.34535 0.00001 TD
0 Tc
(v)Tj
0.48509 0.00001 TD
0.01 Tc
(al y lagrimeo. A la e)Tj
8.31459 0.00001 TD
(xploraci\227n, rea)Tj
6.1378 0.00001 TD
0 Tc
(-)Tj
-20.28284 -1.10457 TD
0.01 Tc
-0.003 Tw
[(lizada por el Servicio de Oftalmolog\222a, se objeti)25<7697>]TJ
0 -1.1045 TD
0.076 Tw
(un e)Tj
1.795 0 TD
(xoftalmos bilateral moderado y una mot\227rica)Tj
-1.795 -1.1046 TD
0.302 Tw
(ocular normal. Se estableci\227 el diagn\227stico de)Tj
0 -1.1045 TD
0.222 Tw
(oftalmopat\222a de probable origen tiroideo \(no se)Tj
T*
-0.022 Tw
(consideraron indicadas pruebas complementarias\),)Tj
0 -1.1046 TD
0.065 Tw
(se recomend\227 a la paciente tratamiento con l\207gri-)Tj
0 -1.1045 TD
0.054 Tw
[(mas artif)20(iciales, y a la Secci\227n de Endocrinolog\222a)]TJ
T*
0.029 Tw
(la in)Tj
1.7887 0 TD
0 Tc
(v)Tj
0.4951 0 TD
0.01 Tc
0 Tw
(estig)Tj
1.9335 0 TD
0.029 Tw
(aci\227n de una posible EG. Se determina)Tj
16.06556 0.00001 TD
0 Tc
(-)Tj
-20.2828 -1.1046 TD
0.01 Tc
0.194 Tw
[(ron entonces los ni)25(v)15(eles s\216ricos de T4L y TSH)]TJ
22.41947 55.32413 TD
0.109 Tw
(\(normales con tratamiento\), Ac anti-TPO \(positi-)Tj
0 -1.10455 TD
0.044 Tw
[(v)20(os\) y anticuerpos anti-receptor de TSH \(Ac anti-)]TJ
T*
0.152 Tw
[(TSHr\), que fueron igualmente positi)25(v)19(os: 40 U/L)]TJ
T*
0.025 Tw
((VN inferior a 10).)Tj
0.97758 -1.10455 TD
0 Tc
0.245 Tw
(Puesto que estos anticuerpos son virtualmente)Tj
-0.97758 -1.10455 TD
0.067 Tw
(patognom\227nicos de la EG, y puesto que la normo-)Tj
0 -1.10454 TD
0.078 Tw
(funci\227n tiroidea en esta enfermedad es menos rara)Tj
0 -1.10453 TD
0.01 Tw
(que la hipofunci\227n, se suspendi\227 el tratamiento con)Tj
0 -1.10455 TD
0.22 Tw
(tiroxina para comprobar el estatus de la funci\227n)Tj
T*
0.206 Tw
(tiroidea intr\222nseca \(que no puede establecerse en)Tj
T*
0.078 Tw
[(presencia de tratamiento\). T)35(ras dos meses sin tiro-)]TJ
T*
0.037 Tw
(xina oral la T4L era de 0,47 ng/dL (VN: 0,7-1,7) y)Tj
T*
-0.005 Tc
-0.001 Tw
(la TSH de 54,01, por lo que la paciente fue diagnos-)Tj
0 -1.10454 TD
0.057 Tw
(ticada de hipotiroidismo primario franco en el seno)Tj
T*
0.099 Tw
[(de una EG y se reintrodujo tratamiento sustituti)25(v)19(o.)]TJ
T*
0.029 Tw
[(Hasta la actualidad (abril de 2006) el e)15(xoftalmos ha)]TJ
T*
0.325 Tw
(permanecido sin cambios \(re)Tj
12.33661 0.00001 TD
(visiones anuales en)Tj
-12.33661 -1.10455 TD
0.259 Tw
(Oftalmolog\222a\), y la funci\227n tiroidea \321con trata)Tj
20.28285 0.00001 TD
0 Tc
(-)Tj
-20.28285 -1.10455 TD
-0.005 Tc
0.025 Tw
(miento\321 es normal. )Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
13 0 0 13 338.0646 384.6219 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(DISCUSI\356N)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 271.5408 360.322 Tm
0 Tr
0 0 0 1 k
0 Tc
0.194 Tw
[(Al diagn\227stico de EG se puede lle)15(g)5(ar por dos)]TJ
-0.97758 -1.10454 TD
0.078 Tw
(v\222as: la que parte de un paciente con hipertiroidis)Tj
20.28283 0.00001 TD
(-)Tj
-20.28283 -1.10454 TD
0.036 Tw
(mo, que consulta en Endocrinolog\222a, y la que parte)Tj
0 -1.10455 TD
-0.007 Tw
[(de un paciente con oftalmopat\222a sugesti)25(v)25(a, que con-)]TJ
0 -1.10454 TD
0.002 Tw
(sulta en Oftalmolog\222a. En el primer caso, la demos-)Tj
T*
0.194 Tw
(traci\227n de unos Ac anti-TSHr positi)Tj
15.24817 0 TD
(v)Tj
0.48022 0 TD
(os en suero)Tj
-15.72839 -1.10455 TD
0 Tw
(conf)Tj
1.75684 0 TD
0.23 Tw
(irma el diagn\227stico. T)Tj
9.38593 0.00001 TD
(ambi\216n lo conf)Tj
6.4386 0 TD
(irma la)Tj
-17.58136 -1.10455 TD
0.014 Tw
[(e)15(xistencia de la oftalmopat\222a, pero \216sta es poco fre-)]TJ
T*
0.023 Tw
(cuente y no suele aparecer en ausencia de anticuer-)Tj
T*
0.051 Tw
[(pos. Cabe, por \234ltimo, un diagn\227stico de e)15(xclusi\227n)]TJ
0 -1.10454 TD
-0.002 Tw
(en sujetos hipertiroideos sin anticuerpos y sin oftal)Tj
20.28283 0 TD
(-)Tj
-20.28283 -1.10455 TD
0.081 Tw
(mopat\222a, pero sin bocio o con un bocio difuso \(no)Tj
0 -1.10454 TD
0.025 Tw
(nodular\) \(3\).)Tj
0.97758 -1.10455 TD
0.013 Tw
(En los casos en los que el s\222ntoma-gu\222a inicial es)Tj
-0.97758 -1.10455 TD
0.066 Tw
[(la oftalmopat\222a, se debe in)40(v)15(estig)4(ar siempre el esta-)]TJ
T*
0.068 Tw
(do de la funci\227n tiroidea. Si se comprueba hiperti-)Tj
0 -1.10454 TD
0.015 Tw
[(roidismo la enfermedad de Gra)20(v)15(es es se)14(gura. Si no,)]TJ
T*
-0.03 Tw
(el diagn\227stico requiere la positi)Tj
12.40558 0.00001 TD
(vidad de los Ac anti-)Tj
-12.40558 -1.10455 TD
0.024 Tw
[(TSHr)40(, en ausencia de los cuales \(aunque puede tra-)]TJ
0 -1.10454 TD
0.076 Tw
[(tarse de una limitaci\227n de la t\216cnica\) resulta a)20(v)15(en)-1(-)]TJ
T*
0.07 Tw
(turado establecer con certeza la EG. En ocasiones,)Tj
0 -1.10455 TD
0.033 Tw
(con el paso del tiempo, el paciente acaba sufriendo)Tj
0 -1.10454 TD
0.108 Tw
[(un hipertiroidismo o se acaban positi)25(vizando anti-)]TJ
0 -1.10455 TD
0.025 Tw
[(cuerpos pre)25(viamente ne)15(g)4(ati)25(v)20(os (4).)]TJ
0.97758 -1.10455 TD
0.193 Tw
[(Es posible la coe)15(xistencia de una oftalmopat\222a)]TJ
-0.97758 -1.10454 TD
0 Tw
(sugesti)Tj
2.75244 0.00001 TD
0.041 Tw
[(v)25(a de EG y unos Ac anti-TSHr positi)25(v)20(os \(es)]TJ
-2.75244 -1.10456 TD
0.245 Tw
[(decir)40(, de una EG\), junto con un hipotiroidismo,)]TJ
0 -1.10455 TD
0.197 Tw
(situaci\227n que algunos autores denominan \307enfer-)Tj
ET
0 0 0 0 k
14.173 7.5279 29.435 12.314 re
f
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
12 0 0 12 14.1732 11.6477 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(766)Tj
ET
0 0 0 0 k
137.36 10.6629 228.784 9.179 re
f
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
8 0 0 8 170.0444 14.3792 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
(ARCH SOC ESP OFTALMOL 2007; 82: 765-768 )Tj
ET
0 0 0 0 k
14.173 668.976 473.386 9.178 re
f
BT
/F2 1 Tf
8 0 0 8 14.1732 672.6915 Tm
0 0 0 1 k
(MACI\347-BOBES C, et al.)Tj
ET
0 J 0 j 10 M []0 d 0.3 w 
0 0 0 1 K
14.173 668.976 m
487.559 668.976 l
S
Q

endstream
endobj
7 0 obj
<<
/Length 4082
>>
stream
/GS0 gs
q
0 0.157 501 700 re
W n
1 g
0 700.157 0 0 re
f
Q
/GS1 gs
q
/GS2 gs
0 0 0 0 k
14.173 408.1469 473.386 240.986 re
f
Q
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 14.1732 641.6219 Tm
0 Tr
0 0 0 1 k
0 Tc
-0.001 Tw
[(medad de Gra)20(v)15(es hipotiroidea\310, por analog\222a con la)]TJ
0 -1.10455 TD
0.01 Tw
[(EG eutiroidea. En un estudio realizado en Sing)5(apur)]TJ
T*
0.029 Tw
(sobre m\207s de 1000 pacientes con este tipo de oftal-)Tj
T*
0.199 Tw
(mopat\222a se comprob\227 que s\227lo un 1,9% no eran)Tj
T*
0.043 Tw
(hipertiroideos, y de ellos s\227lo un 0,2% eran hipoti-)Tj
T*
-0.002 Tw
(roideos (2). Se han publicado casos aislados de esta)Tj
0 -1.10454 TD
-0.026 Tw
[(v)25(ariante de la EG, en ocasiones con formas de oftal-)]TJ
0 -1.10453 TD
0.01 Tw
[(mopat\222a se)25(v)15(era, con hipotiroidismos muy marcados)]TJ
0 -1.10455 TD
-0.0001 Tc
(y)Tj
0.94846 0 Td
0 Tc
0.199 Tw
(con t\222tulos muy altos de Ac anti-TSHr (5). El)Tj
-0.94846 -1.10455 TD
0.068 Tw
[(mecanismo f)20(isiopatol\227gico implicado parece ser la)]TJ
T*
0.109 Tw
(capacidad de inhibici\227n de la funci\227n tiroidea por)Tj
T*
0.029 Tw
(parte de alg\234n tipo de Ac anti-TSHr: la mayor\222a de)Tj
T*
0.106 Tw
[(estos anticuerpos son estimulantes del receptor)40(, lo)]TJ
0 -1.10454 TD
0.056 Tw
[(cual se traduce en hiperfunci\227n y bocio, pero e)15(xis-)]TJ
T*
0.006 Tw
(tir\222a un subgrupo no estimulante \320que bloquear\222a el)Tj
T*
-0.031 Tw
(receptor (4). Con los m\216todos anal\222ticos disponibles)Tj
T*
0.002 Tw
(actualmente en la cl\222nica habitual no es posible dis)Tj
20.28284 0.00001 TD
(-)Tj
-20.28284 -1.10455 TD
0.025 Tw
(tinguir ambos subgrupos.)Tj
0.97758 -1.10454 TD
0.281 Tw
[(En resumen la EG con hipotiroidismo e)15(xiste,)]TJ
-0.97758 -1.10455 TD
0.086 Tw
[(aunque es e)15(xcepcional, y a su diagn\227stico se lle)15(g)5(a)]TJ
22.41947 20.98635 TD
0.092 Tw
(siempre a partir del estudio de funci\227n tiroidea de)Tj
0 -1.10455 TD
0.025 Tw
(un paciente con oftalmopat\222a.)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
13 0 0 13 325.4232 591.1719 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(BIBLIOGRAF\352A)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F0 1 Tf
9 0 0 9 265.2874 571.1718 Tm
0 Tr
0 0 0 1 k
0 Tc
0.16 Tw
[(1.)-640(P\216rez Moreiras JV, Coloma Bockos JE, Prada S\207nchez)]TJ
1.38977 -1.11111 TD
0.234 Tw
(MC. Orbitopat\222a tiroidea \(fisiopatolog\222a, diagn\227stico y)Tj
T*
0.025 Tw
(tratamiento\). Arch Soc Esp Oftalmol 2003; 78: 407-431.)Tj
-1.38977 -1.11112 TD
0.164 Tw
[(2.)-640(Khoo DH, Eng PH, Ho SC, Tai ES, Morgenthaler NG,)]TJ
1.38977 -1.11111 TD
0.098 Tw
(Seah LL et al. Graves\253ophthalmopathy in the absence of)Tj
T*
-0.021 Tw
(elevated free thyroxine and triiodothyronine levels: preva-)Tj
T*
0.089 Tw
(lence, natural history, and thyrotropin receptor antibody)Tj
T*
0.025 Tw
(levels. Thyroid 2000; 10: 1093-1100.)Tj
-1.38977 -1.11112 TD
0.024 Tw
[(3.)-640(Teissier MP, Lopez S. Orbitopathie dysthyro\225dienne: phy-)]TJ
1.38977 -1.11111 TD
0.052 Tw
(siopathologie, \216quilibre hormonal. J Fr Ophtalmol 2004;)Tj
T*
0.025 Tw
(27: 806-809.)Tj
-1.38977 -1.11111 TD
-0.005 Tw
[(4.)-640(Kazuo K, Fujikado T, Ohmi G, Hosohata J, Tano Y. Value)]TJ
1.38977 -1.11111 TD
0.018 Tw
(of thyroid stimulating antibody in the diagnosis of thyroid)Tj
0 -1.11112 TD
0.269 Tw
(associated ophthalmopathy of euthyroid patients. Br J)Tj
0 -1.11111 TD
0.025 Tw
(Ophthalmol 1997; 81: 1080-1083.)Tj
-1.38977 -1.11111 TD
(5.)Tj
1.38977 0 TD
0.093 Tw
(Jorge Z, Nobre EL, Santana A, Castro JJ. Doen\215a auto-)Tj
0 -1.11112 TD
0.025 Tw
(imune da tiroideia. Acta Med Port 2005; 18: 88-92.)Tj
ET
0 0 0 0 k
461.93 8.5039 25.629 11.338 re
f
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
12 0 0 12 469.559 11.6477 Tm
0 Tr
0 0 0 1 k
0 Tc
(767)Tj
ET
0 0 0 0 k
137.614 10.57 228.784 9.178 re
f
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
8 0 0 8 170.2989 14.2856 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
(ARCH SOC ESP OFTALMOL 2007; 82: 765-768 )Tj
ET
0 0 0 0 k
14.173 668.976 473.386 9.178 re
f
BT
/F2 1 Tf
8 0 0 8 390.2957 672.6915 Tm
0 0 0 1 k
(Oftalmopat\222a e hipotiroidismo)Tj
ET
0 J 0 j 10 M []0 d 0.3 w 
0 0 0 1 K
14.173 668.976 m
487.559 668.976 l
S
Q

endstream
endobj
8 0 obj
<<
/Nums[0<</S/D/St 765>>]
>>
endobj
9 0 obj
<<
/BaseEncoding/MacRomanEncoding
/Type/Encoding
/Differences[32/space 40/parenleft/parenright 44/comma/hyphen/period 48/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon 65/A/B/C/D/E/F/G/H 74/J/K/L/M/N/O/P 82/R/S/T 86/V 89/Y/Z 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v 120/x/y/z 135/aacute 141/ccedilla/eacute 146/iacute 149/idieresis 151/oacute 171/acute]
>>
endobj
10 0 obj
<<
/Subtype/Type1C
/Length 8239
/Length1 8239
>>
stream
  FXYGCU+Times-Italic   @¯ ¯¯¯¯˚=˚m˙Ü˙
 ãã
 ãã  7  3  ∆ª  ˇ ∑√»003.001Copyright (c) 1985, 1987, 1989, 1990, 1993, 1997, 1998, 1999 Adobe Systems Incorporated.  All Rights Reserved.Times is a trademark of Linotype-Hell AG and/or its subsidiaries.Times ItalicTimes  F  " 3 $ )  4 0 & 1 ' 5 - .          	 S D I P T Q G U B M N 
   œ F [ J + 7  # L E » O C ” H ÿ Z   , % / ( W } Y V  ’ R K : ; Œ H   xYËÎpøN∆GôÓ}‘Uü'pﬁ)Dâ	<	—

ï*©!©˘ÆÏgﬂ9ó¸O•ŒkÙè8∫1öQ∑/úﬂvﬂW«4^
ë¸yÏm‹•¸$dãõ˜fØ¯*wX˜˚¯˚˚<˜<Ë¯˘0˚∂¸àÙ9˚ ÇàeÇ{˜Oõ]è~ê•°ëòô¶ƒ˜˜pü˚ç}ã}ãäcqÖWá{˜äõQêÖñ—-¯ ˚o¸*˜)˜óå∑˚ódãõˇ6Ä ˇ "Ä ˜ö©{õ¯wÙÿ¯ÀõUç{Æ~Æ.˜â˜#¶¡—⁄˜$˚@ãg˚å{∫Ö£âdÇhàÄ˚¸NyLâXÇ{˜àõUí}ç±ìãèó∏√˜eÃÜ˜˚ÿ˜(Ë˚ó¯Áùíèï∏ƒ…t5@f=˚$pÉåèsúy∏¯ÔØÕ˜˘ ¯e∞˜[vÅÜÖntN£C˚y˚E˚q˚U˚\˜&E˜˜&‰Ù∑∞zô[\ED˚ã˚Tﬁ˜˜'Ò˜Ü˜\˜#î˚oç”ãõ˜ µ˜°õÉ˘õ˘ì˘!˚ã{∂Ü¶àhyÜsÖw]˚8˚±¡˜WùÕªêÆéõ˚•{Ωá¶ÜiyÜsÖw˚¸NzM|àZÇ{˜äõ_ëpé≠ëåìçîÕ˜à˜±J˚ÄyKfá]Ö{˜•õ]èkéØëåìçî˜¯uú õçºî¸$˚*yÆÄv˘¨æù…„˜‚º¯h¯h≥˜[tyÇÉtwëíxëysë^.<H*JêÄ˜˚'¨h∞lKYh9-1S⁄‰ìåêåìwç|i˚sùºòèíüß≠æg–˜—ÛÈÕv≤/Á4‡£∫Œæ¨¬˜é"Rå”y¨¯˛¨«Ù¯AÙ˘O¯;˜<˚÷˚˚G˚x˚n˚q˚R˜T‡˜t˜X˜Ñ˜]¸™˚Ü˜Ô˜÷˜ZÍØE0˚+˚„˚_˚ã˜#¢dã¨˜ª¨˜ó¨{õ¯‹ûË˘˘!¸Öÿ{æá•ÜhÄÉcàÅ˚¸NzM|àZÇ{¯è…˜6{ìD(`e˚Uãq`é™óèùÀ˜{˜7ÜããZ{à{á|üÜœ˜|yèÅuÇxÇ}ulÖÇ˚5âËÕ˜}ëüçë”ã˜2¶|Mä~ä{†âdãõ˜µ∞˜≠©{õ¯äÚÿ˜&˘µÜ®àf}ÅcÑt˚
¸=yK~âXÉ{˜âõWí{ç≠úããó∑¿˜U°Üôà—ã˜\ƒ˜’Ë˜+˚;å_˚å˜DQóèëõ©˜©aA˚9˚ãB~çéwdãõ˜…Ø˜ó¨{õ¯Áùÿ˘˘!¸Ü{øá§âfyÑmá}˚¸NyK~âXÉ{˜êõiçaç≥ñéóë°…˜sûä≥âºãú¨à_vÜtà}úÜ◊˜~yê]1âã˚<àËÕ˜}í¢ñé ã˜(Ø~L}â}ä}†â-ãõ¯ÓÆ¯”ô˘˘!¸®a˚.ùá≈˜Ωã˜ã˚$¸§yI`á^á{˜∂õ@ê|å¥ôèöìß˜¯Ü¬À≥{DÄä~â|úâ-ãØ¯ÌõÉ¯À¯'˘!˚•{Ωá¶ÜiyÜsÖw˚¸NzM|àZÇ{¯ë≈˜GwëI˚&:à˚ãWYãÆéãèåèî±˜¯OùÕªêÆé˜Kãõ˘õy˜˚˙–˘˝˘!˚;˚·¸}àT¯}˚I{¬äûzvÇÄlÄc‡!¸j˚wÑ^Ñ{˜Zõkçdê≥íè£êû˜¯;è«¸¨ú¯¯Ωé˚¸b}WtzKÖ{˜•õRêwç∞üêûë†˜¯Oú óç¿î˚*ã◊¯£‘¯·¯$˜gz{pI˚Rê˜T˜T˜˜§∏ãŒ÷SÁ!r˚á˚0U†Ñô§±–ÂãÿπOMjáQ˚ ˚)˚f˚tz˜˜Ω˜˚*Ñß˘ß´⁄˜«⁄˜˜0Ï”¯˜)·ã%m˚C5˚‘˚kTû˜¯˜¢Ìp˜,˚˚˚:˚b˚¢#ƒ$Û˜<˜˜˜Z˚*òv¯Ì‘Åï÷¯b∞¯≠˘$Öï–¸:˚ôÇ≠≥¶´”ã˜rçà¸¸Í—˚—†v˜ﬁ˜ãwÒÀ{˜∞Ø˚ƒß‘ Œ∂r®iÉaÜa_∏äãifTfw~»˜F¯N†Æõ±´r§lmrsjd≠|†˚*Ñ°˘¢©œ≥Ÿ˜-÷xœÙ©˜1m†˚˜G¯˜€‰·Ÿc»@÷Ù¬ù˜ØÏ˜˚ ¨I-4Z$W•\»JÙsÑ˚?X˚%œà˜˜¬•ì¯Ï'§qJ+=aUÙ5V«⁄˜
¯Œ±∑À‹•F[8PoTq,·ã™•˚—ïvã˜˜z˜ãwΩ˜Ä˜òıÄ†≠õ±X´q§nlrqlòe≠{°§Ó˜È†Æõ±´r§lmrsjd≠|†˚*Ñ•¯úzØ˜sõ©◊˜û‰‹¯ú˘B˚≈x˚M˚è˚b˚8ÓV‹˜>‹˜=º˜"&µG{|âá|‹|à}Ü}Ñáç£Ω˜˜=˜D¢˚ü˚ó◊µ[91U˚@˚)ã˜•õï˜Ç˜˚*Ñµ¯ƒ“˜Ú–˜Ç¯Á˜z¢“˚î#˚n|˜rÚu˚-4B˚)Ur¬ã^xvno©o”˜Wˆ˜.˜˜1”˚•˚—†v˜T º˜}˜Æ˜ì˚o}L˜p˚—†v˘"wÆwµ–∞˜3˚C[˜ã„Œ ú˜≥˜–ª˜æ¡ªΩ∞~ö˚J˚/=˚0ã˚9Kã˚&Ó˚8˚ô†v˜ËJÃdó∏¯»˜¥˜ô∏±”®öì«˜™»£|gã∂ñØãø≠rötL?˚	IjÉwâçº˜[àçò^ÑP~XÑzçññéñ™ê{}ÇÖiÅf:˚∏˚bÄØ¯4v©·˜r‚˜Úıcg\bONm∏ÿÎ–˜E˜ùüÜ|z|Öãqtö}§§°ùß™rΩ7˚(˚˚-˚!˚ﬁrÃÙ≈÷´§˚*Ç∫zv¯æˇ «Ä ˇ Ä °w˜¥⁄éŸ¥¯e˜	[eslwÉÉíój†‹˜îãÆÃ]íu1%˚.Ylâç˜
¯KÜêrWVÇWÖ{•å¨äì~ã|{RÄa˚¸â÷¨˜ö¬∏œüßﬂ˜ΩãõãòÅãz¥~9˚≥ãqpòx´Õ∂…øØ˚*ïv¯Xv¶ﬂ˜•ﬂ˜’¯M˚&˚(˚5˚'8∏Nı˜-˜˜I˜Õl›˚Ñvª°_W <˚c˚YmØƒ˜
Ê˜[˜˚ôïvû˜˜1˜Ö¢˜‘π◊•õúØ˜&w˚3õ\ñëèïôú®≥xã©√Ë§˜‡˚‰ã º´î°ûÃ£QRêÆõúü˜}¨ÉÜÖÅzúmwúã^!};l>˜+ãIj{[S:{Á∑Ñ˚*˚aö˜Gû¯∂ãw@˜!∞ô˜öÂÓ¯˜Õ˚1˚N˚rrñ•≤≥˜§Àœ•≈π∫ÃåQp˚◊Â¢åé†ùzv%¸p˚kÉÖpV{˜aöqeã´üß˜î≠¢üÜ§˜˜4˜:˜/”m∆29RBhsâç¶Ëåéåéãçèàåâﬁ˚/u¸˚Nv¯Ô´˜x°˚'◊¯4⁄Æ¯ Â3¸8Écq˚KãÑììñîããú£sò}âgâãeà]ë¥~™˜	√˜5˜ß”˜‘˜ë´˚ æî©˜E›òïáÉÄÅããuÄëp´¢ùüüü{∏C˚Y˚96q/¸Äº˜˙´∞‹:˜ó–˜º¯@;ßÚãçåçãçêâèááÉàÑÜá‡oh[^jzzÇoÑÖÇâàäàãáãâåâãâ’C˚ßá{xNã|mßÅüø≤∑ÿæ~írkh\wãÄÜìîéãçåé„˜·ﬂ˚*Äº[æ¯!wå°úﬂ˜X‘Üúl¯d˜_^wr|ÉÖëí™Á˜ÈéóÑéöNÑààÅ_âßàj•`˚˚-˚O˚'né2Ôú«¿©˜ﬁçâ{NÜuãtzãqµ∂≠Ø’«¸îÂÂ˜p˜	ö®ßx[))˚l!úpjù¿¸Ä∂¯Ùõ°w¥ÿ–˜x˜LZvor|ãôëñì¶çî∞˜+¯◊Üê–WWÇWÖ{ô§®àuv˚%¸ûãvoèi∑…≤ªÿæ”Ç∫zv¯ø\õ˜ˆÿﬂ◊ç⁄¨˘E˜	\eqkxàéújô‹˜†ã≠≥t¶gI:3˚Eâçô≥¢ﬁãôµv¢e7$˚/Zmâç√˜\àçZVÄVÅUÅ{ºöâuu9˚Æ{I÷∞˜üÕ≥«j≥¶◊∏îòãpxF˚äq*÷®˜ú ª◊™º”„¥ãóãîÉã|¨w=˚´ãp}ãhµ√Ω√æØêí˚—†v˘1w˜p–®˚H˜(˜˜˜:˜Q˜p˜C˜	xÜ•T¢(ã 3{˚b˚^˚QN_]¸$ïvã˜¶˜†›Ä†Æú∞`™q•mmrrk†e≠{†˚*ãö¯ˆò±wº˜¸º˜´ö}`nêßõò∞êü˜#¯õéïéñãìèäéàÉ˚mÉ\|ƒçîã®ããkÉá}àÄ˚¸Ä~^càPÖ˚bÄ∏¯¢˜sw™‚˜xÕ˜,˜ê‰∞œÿ¡§ïxvÉÜ˚˚ba˜s(bYaiUaW¢œüêüê†ßè˜6¢È‹ã⁄∑l£X˚!˚2˚<˚#L´=ÙÔÊÁõñ”¯ãñíëíöù|úvÄÉáÖÖ˚6˚4Æ˚bÄ∏¯¢™‚˜xÕ˜,˜ê‰∞œÿ¡§ïxvÉÜ˚˚ba˜s(bYaiUaW¢œüêüê†ßè˜6¢È‹ã⁄∑l£X˚!˚2˚<˚#L´=ÙÔÊÁõñ˚ôOvÌv¯«˜∫–‹˜…√°†é±˜&˚ ¸îÇòñöíúã—”5ã÷æ∂∞±´rêÇt}zuôÄãÄ~{àÅxã¨qWŒzûIô˜∂˜Ïñ˚∞l˚¸Ä∫¯ õ§w˜ıº÷∂Ïº˜r˜QbnwÇÑìíóó≥èô„˜÷àç‹dÑ8{eâ{¬ìÜvo<˚åã\yã_∫√∑¬∆≤®¯Ñ°z¨jstxhh¢z§¨õ™ü˚by™˘õÖË¯˘!˚í{∏á´àhwÉoá|˚¸eÖwÇiiãrÅô§ïåîãë§u°qnztlN«p¿˜≤Ûı®Ú¯ùÀòçæìdév˘#õ¯…˜˘D˘!˚N{ûâ∑áno`AÇ{˚^˚ÒÜJ¯Häëãêãê¥©è∫êõ˚Ö{√ÑéÜü˚‡¸úû¯	¯˚ëïû©™ã¸$˚˜z“Àê˚ƒß‘ Œ∂r®iÉaÜa_∏äãifTfw~dã©˜¡™˜ô©{õ˜cı˜
˜ W“É˜Æ‘˜˜…˜ÌE©V¢ç⁄ÈûŸ∂Â˜+≠#˚ñ{∫à©àfzÜuÖt˚¸NzM|àZÇ˜G∆ûø˜AöÀ‹œäπä§{©x£hãXã(R<˚!ã⁄njí±Í˜"¯úöèéò¬÷∞gG˚˚y.ÄÄåãÅ˚bÄøwv¯0õ˜hõ°wô¯S˚˜¥¯2˜YnÅyuqxπ˜?Cj˜˜±©ºçõ˚K{¶ßãxl˚+T`âç˜¯YÜêtWWÇWÖ{ô§®àuâuuAÇg˚¸w÷ª˜Hµ´¥ïm±3ót©Pùt™ã∑ã®∞±”˚*~¿Xª¯¢˜^úùwö‚˜M◊Ñöu˜7∞NãƒúÊÍ˜l˜∫ã_t˚)˚R,Æ˜¿’[awtwÅÉíöõ˜¯>∂˜BÜêuXÄXÑXÜz¬äíÜt}ÑrÉo`˚3ââá°Ñ¨Sã˚˚>˚K˚+W†IﬁvΩ√ú˜”çâÉhátãtvìr≤¨Ã∫Œ∂˚*Äº[æ¯!wå°˜swúﬂ˜X‘Üún¯d˜_^wr|ÉÖëí™Á˜ÈéóÑéùNÑààÅ_âßàj•`˚˚-˚O˚'né2Ôû«¿©˜ﬁçâ{NÜuãtzãqµ∂≠Ø’«¸îÂÂ˜p˜	ù®ßx[))˚l!ûpjù¿ù¯¯ñíëíöù|úvÄÉáÖÖ˚6˚4Æ˚*Ç∫zv¯æ\õ˜≥÷ä‹®¯`˜	\frkwâ}çöd©€˜ãã∂µt£]8/˚A\âçÀ˜eàçXUÄUÅUÅ{¡ïÄ|vH˚~l˚÷¥˜ò∂π–d√Ø ·ªûë}y®cA˚àãsnçmπ¡ÆπŒΩ˚*Ä¢¯º˜^úùw¢·˜´‡Ï¯˜«7,˚g˚\ã•íÙÎ˜Ü˜ ïUl˚™˜‰≈äíÜt}ÇrÑo˚¸âáuÿl¿˜-˜;˜A˜2‘ZªE1L.Wjâå‹≠˜π˜N°›ÜêÏWÅXÑYÖ¸Ä∫¯ õ§w˜áwº÷∏˜r˜QbnwÇÑìíóó≥èô„˜÷àçÿdÑ8{eâ{¬ìÜvo<˚åã\yã_∫√∑¬∆≤Ú¯Öñíëíöù|úvÄÉáÖÖ˚6˚4Æ˚*˚b°˜¯v˜k≤ô°ì¬¨Ÿ˜+«j⁄˛¯l¯)NÑÇîîzﬁîyrîb9˚Q˚F∂sØ{it`nlxöóÇ7TjuRT¿S˜˜Ÿ»‡˜˚i{ã¿ò°¶ôòôáãò˝„Í›’üàüÖûΩﬁ˚'¸[YZ^1|˚ èË¢ã¶¥Æéé≠¶ëìÏfÇùûÇØz^›¶¯L8Y+I^z¨∏Œ∑Òÿµönd˚*ïv¯Xv˜àw¶ﬂ˜•ﬂ˜’¯M˚&˚(˚5˚'8∏Nı˜-˜˜I˜Õl›˚Ñvª°_W <˚c˚YmØƒ˜
Ê˜[˜˜0˜Hñíëíöù|úvÄÉáÖÖ˚6˚4Æ˚b˚b¬Tﬁ¯£ò£w¯≥®ö¯$éóíåöƒò`0¶úUµ˚CepaZrnci~Ç{Xy~ßãmvzzvòa∂àì˜˜¨¯f˜Øw•fqÄv}]¡ñãbV<˚`Ew˜~÷P˜F~ãy={É[˚*Ñ±¯Ôµ˜Ÿ€p‚–˜F¯ÀüöÆ∫ ±ºsH˚ ˚_'}å{íåìãíã‡„÷a˚˚-iiSj«ã]fÅyv^¬}∆˜MÊ˜"˜˜F©qóé–Ù≤ΩÆ◊ﬁCµAR@_Or˚*†v˜F ¯Gwå¯r˜©˜Ö˚hè˜ƒ˜“è€˚÷,˜¯Gb¸5¸CwH˜öZ˚F⁄π˜DÔúãõˇBÄ ØˇÄ õí˘_˘f˘!˚r{¬Üëàzr?KG[˚$&Öåæ˜PùÕΩê¨éõ˚•{Ωá¶ÜiyÜsÖw˚¸NzLâVÇ{˜åõVëxç±ôêóî´«˜oìä˜˚Zóv•[ãruvâUÖ{˜ßõPëÅåoº˚B˜√˜¿˜víêÆ•¨ê”ã©¯Â©{õ˜cı˜®˜∏˜˘æá•ÜiwÉlàÄ˚¸NzM|àZÇ{˜ë˜∫˜5˜M˜^ÿÙM˜5˚z˚™˜KPôèèöƒ˜E≠˚&Nj˚»˚œ\së¨õò∑î¨úëvöõ˘õw˜¯~˜x˘k˘!˚[{¬áöÅdzÑxá}&¸à˚b¯É˚5{ªà†{úf˚¸5f˚ÄÅTÉ{˜Zõnçbé≥ìçùí•˜¯4è®˜x¸¥ù˜$¯ã≠˜êôÃô”y∞˜∞õ˜Õ≠ø˜˘X˘*|èÅ}}wdãqM≠ã6˚j˚S˚Y˚y`®˚k˜ú‘È°≥Àº˜OúÀ¶è¿èõ˚û{¡Ü£àn{g˚BnttnrÄX˚>k˜Ÿ˜8Ì˜ã˜]“Ôj˚îùà˚bév¯:ó§w˜“˜<æÿ†¯'åïìãìºéu=ôïQò˚6Czã~îöùü“Õ∏¨Æ˜)˜FÁ∞s•jw{}|UµñãdY;˚RPlkÑ˜Ö›m˜ûÜäåÉâÜZ}ÄB˚—†v˘,w˜H˜s¯¯Ïñíëíöù|úvÄÉáÖÖ˚6˚4Æ˚bÄ¬T≈Qÿ˜¬‘S√f∞p¯nä¯&˜mpwfvwÑ§õáÖ§i˜ùãœ˜®í°ízã££ïûùä£uóxW\N9WÄ¬y„|ãuãkIsÇpFè|´ìôéîã¶è}lîåÜ≠˚Ç˚1qiz*yyûãuuy{äsõx¨™óñûú≠∞µ¡ªÕ©˚Vòö}®¢®ã˜“˚*Ä¿X∫˜˛ôùw®wµÿ˜>ŸV¯a˜	_hohxÄäñêöò∑ëü⁄˜øAd uLZAéWiL-`zÜòóéãéåéÊ˜ˇàç¶YYÇYÖ}¥ûãnp?˚êã__û|ØÂ’˜˜œéNt9w7y|çf∏Ω••Ê ˚*èv˜äπùv¯•–„˜ò÷º¢z˜¡Ø˜<˜}˜^˜(;’$˚	˚˚˚‹˚ÕH‡∑∑û•≥èâÄ`˚˚Y˚Jl˜¯/Ëª˜%˜Óã˚ dp{%rd`oSzl'áÙ´¸Ä∫¯ õ§w‚Ìº÷EÌÒÌ∫˜r˜QbnwÇÑìíóó≥èô„˜÷àç⁄dÑ8{eâ{¬ìÜvo<˚åã\yã_∫√∑¬∆≤∂˚¯ãwm|jn°v¶¶°°¶¨lõz˜\wm|jn°v¶¶°°¶¨lõz˚*˚eù˜H¿¯°§·˜°ô¯˚S|qjé•éåèåè˜8¯’B}_â•Ç~¨S˚˚5˚R˚G•Rÿ‰≈‹ÿ¿çâ5˚±}^ráTá{˜Ö˚¨˜Ÿ˜˜˜OË™®v^)˚ ˚i"hv™∂¸˚c¢ˇHÄ ˇ Ä §w˜ı˚‹˜rÏº∆à>xr#XÇÄåïóòãã††wöwfáháZ∏|¨‰≈÷˜4¥Û¯/àç‹dÑ1{bâ{≠å≠àêÑãzåâãàà~ÜtÄb˜%˜ °z¨jstxhh¢z§¨õ™ü-ãõ˘õŸ¯ø˚˜‡Ê˘øÉìäõRÿ˚°N˚hxIdá\á{˜µõEêxå∞®† õ¡®–˜o˜¢´≥ñì¶òõ˚Q{æÜùâpa˚#˚2^SsÁ`˜¶´•çπèõ˚É-ãØ¯ŸØÖ¯¯¯Ú˘!¸z]˚&ûÜ≠–°π˜-ã˜?¸s¸Ô}¯ç¡˜<xéZ$fk˚8ã˚5¯w¯Ô˚b˚mÆ‡≠¿Æ¯4v©·”’◊‚˜Úıcg\bONm∏ÿÎ–˜E˜ùüÜ|z|Öãqtö}§§°ùß™rΩ7˚(˚˚-˚!˚
Ãj«ÖU5îÉïèñéñã£°zsãkTrtìíyzn´~≠É£ãº‘ûœ∂g£_ÖäâÇ±√Îë¿—£©yù˘!ú˚Üò˜í˜†é¸tè}ô˘*ô˚vï˜sã˜öì¸|å	´
◊˜é˘
endstream
endobj
11 0 obj
<<
/Flags 98
/Descent -205
/Type/FontDescriptor
/StemH 0
/CapHeight 653
/StemV 76
/FontName/FXYGCU+Times-Italic
/XHeight 683
/Ascent 676
/FontBBox[-169 -217 1010 883]
/ItalicAngle -15.5
/FontFile3 10 0 R
>>
endobj
12 0 obj
<<
/Subtype/Type1
/Type/Font
/FirstChar 32
/LastChar 171
/BaseFont/FXYGCU+Times-Italic
/Name/F0
/Widths[250 0 0 0 0 0 0 0 333 333 0 0 250 333 250 0 500 500 500 500 500 500 500 500 500 500 333 333 0 0 0 0 0 611 611 667 722 611 611 722 722 0 444 667 556 833 667 722 611 0 611 500 556 0 611 0 0 556 556 0 0 0 0 0 0 500 500 444 500 444 278 500 500 278 278 444 278 722 500 500 500 500 389 389 278 500 444 0 444 444 389 0 0 0 0 0 0 0 0 0 0 0 0 500 0 0 0 0 0 444 444 0 0 0 278 0 0 278 0 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333]
/FontDescriptor 11 0 R
/Encoding 9 0 R
>>
endobj
13 0 obj
<<
/BaseEncoding/MacRomanEncoding
/Type/Encoding
/Differences[32/space 58/colon 65/A/B/C/D/E/F/G/H/I 75/K/L/M/N/O/P 82/R/S/T/U 87/W 89/Y 97/a/b/c/d/e 105/i 108/l 110/n/o 114/r/s 117/u/v/w 121/y 146/iacute 151/oacute 234/Iacute 238/Oacute]
>>
endobj
14 0 obj
<<
/Subtype/Type1C
/Length 4641
/Length1 4641
>>
stream
  HOVTWK+Times-Bold   @¯ ¯¯¯¯˚<˚n˙|˙;
 ãã
 ãã  3  /  àƒ  Ë ∑¡∆003.001Copyright (c) 1985, 1987, 1989, 1990, 1993, 1997, 1998, 1999 Adobe Systems Incorporated.  All Rights Reserved.Times is a trademark of Linotype-Hell AG and/or its subsidiaries.Times BoldTimes  )  0 ' 5 " - . 1 ∂  % * 4 3 & $ ) : 8 6 / B T P D M ” O J  V ÿ C S W F ª # , Z X E ( +   X Ωuæ*ûÚıUéçˇc“>…0åá—		F	ë	˝
N
Ö
‹Bû¯Q§ûùà¸$˜x¨˘¨Æ˜E˜ˆ˜E¯˘&˜ ∞˚D˚&4Ö˚˚?˚?Ö˜‚˜&∞˜D˜ ¨˚U˚5˚˚n˚f˜)˚%˜a˜a˜)˜%˜f˜n˚5˜˚Udã§˜ƒ≠˜´≠r§Û˜6˜-§˜£ﬁõ˘∫à¥âI¸xMlàRÖr˜¸§EécçÕ˜}˜õB9ñ§˜Êr<}|E˚ÜÓ˜|∂ùè¡˜@¶L#°£˜]¸Àúã§¯ˇ´ˇ  Ä ˇ Ä ˜U˜6˜Tß¯ï§Aêsç‡¯£–áÚÜü˚4®â˜]¸Ïà˚]®ü˜4Úê—è¸£7sâBÖr˜˘”ã§˜@≤¯Zwî˜˚˘<Ë˘E§á^{ÆÛ_˚s¯¢o˚r¸∏m@}iUÉr˜_§iç[é±õõ¥ß”˜uôk´ApjyäMÜr˜ÿ¸à˜ÄÈ˜á˚áúã§r™˘ §Ù˜6p˘˜wn˚]S8˚+Huìª¯l„™å—é§˚Òr∏à¥âI∞¸xNmàSÑpr¯÷˜∫ã§˘§Ùµ¯ß˜/˙-§Iîué€¯N·´ç√è§˚ê˚\¸l˚\¯l˚ër“Üù}W¸oQ~|=Ñr˜~§8êy£—¯eç˜é¸·¶˜é¯ç¸åInàOÖr˜‡dã§˜™Æ˜√Ær§Ô˜6˜:˜@Ïõ˜‚§Fîxç‹˜N˜åæåÀØ€∏ñ“ãÆã˜=˚Jö;ã˚÷‹r¿Ü™à7¸NS}~ÇÑÜâäZÉÏ˜ä¯Ÿ°åòò≠›Øe˚˚al˚Ä˚ôã§˘§˜˜6¯§TècéÀ¯xœªå∫ç§˚Úrπà∫âI¸xMdáUÜr˜ÚQ˘Œ£öõïßØlìyÅxâqt˚˚1√¸$”ã§rÆ¯Û≠r§Ï˜6˜ï˜B¨ô˜–˜êì˜ ˜0˜L˜.0˜B˚¨˚≈úr≤á∑âN¸ÅfwnLl˜â¯Œìüëû√˜@¢˚i0˚É3K˚[Çù≥˚ôã§˘§˜˜6¯§TècéÀ¯xœªå∫ç§˚Úrπà∫âI¸xMdáUÜr˜Ú-x¨˘™Æ®w˜˜Ö˜P©‰¯x¯o˜mmxÜÜ|tn\¨;ÿ˚Rl˚N]ã5˜?9ŒkÃl∫sãH~Ü(˚Ë˚Q˜wn˚ã®õèêù†™∏iÍ˜LÀ˜„˜?≈iú˚'‘‘7µx°¡Ã¬©ø˜
«˚Eù”ã§˜¥´˜Ω≠r§˜˜6˜K˜?Ï˜®¯Ï™êçñ¬€¥`&˚Wu˚ä¯K˚‘|åù}˚]˜±¡úÚ™ã˜˜<˚hìE˚÷‹rƒá™â5¸N:wàGÉr˜Ê§Iîué€˜X¶˜c˚Õ˜aúã§r™˜æ≠˜´≠r§Û˜6˜6•˜§Øõ˘πàµâI¸xMlàRÖwr¯›≥˜do˚+L%q)Jxó∑˜ÜÓæm˚ó•˜Êq˚|Zp.Ü˜|∂ùè¬˜“r˚"¢§˜]¸’”xª˘	¨àwº˜E¯6§ÿ˘%˜,.8@m=l<ö”afÀÖÎ«˜=≤˜-˜&˜ﬂ˚	4Æ§∏˜~pÿrÅÇvpq>º1˚f˚$˚0˚_˚O˜˚8˜}˜Ÿ ﬁ‘˜ã§˜¡∫˜™§ı˜6˜Ö˜6˘ã§Víhè«¯xÃ∏é∂é§˚Ër∑àπâI˚c˚Ö˜cÕπç∑é§˚Ârµá∂âJ¸xPkÜVÑr˜Â§Vëfè»˜z˜Ö˚zNfáVÖr˜Ë”ã§˘§˜™˜6˜˜˘O˘8˚pr∫à∞âdpkTÑÄ˚˚M˚˜|Éõ{§ãößóë–§˚„ræà£`êÇ˜K˚‡˚'8sâFÑr˜Ô§Eíuçﬁ˜L˜S˜Àü´®èûé˜Úëv˘.§˘¯˜˙i˘8˚Jr≠âÆäbváÄàÅ˚˚Ëâ ˜·ÖûÉ£ãó≠®å∂é§˚ÃrªâñÄòuÆ+˚	˚≈â˚˜˝áñàñãñ∞ßçØé§˚∫rµÖïÅú[˜h¸Óß˜J¯hí˜<¸h¶˜\¯Óó∞°£Æé”xº˘§Ì˜3˜÷∑˘Q˘8˚pr·áóiN˚≈Kâ˚-˚D˚$ã˜ƒ˜‚„™åÕé§˚Êr√Ö•â7˚‚˚ •h∂eRÃÈÖ∑«‚û¡Ωµ∏ô‰∆˜”Õ¢ñ¬ì”évù§˘§Û∑¯C∑xõ˜w§Aìvû”¯$ç∏¯Q¸≤ß¯·ªë¢”î§˚kr‹ÖójO˚√â˚Ô¯?˚gròõàF√x¸nIoÑOÑ˚*}ÀK“¯´§˜&˚˜˜˜¨¯mÀÅÅàààäáãuãûë˜ôÈ2∂˚˚LNLG¡ãóøö±ù≤mìã†õ¢üØ’ôfXBt˚"`˚c#?…lª£—êÃÃoëìa—∏∞£¨ß˚Wƒ{}tpig|Ø™‚Ó®¢ê˚ô}≠˜∆˜Ä¨§§tÔ˜Î`°≤˜Ë˜⁄˜%u“Éàáy¨xb°ã\/HP3˚.˜Çëã/mvgY¥˚sÙ¶Öo˚9§üïëìñîœnΩËÀ∆Í¨˜8˚~tãÒ™ß•Ø≤ƒπ`D†˚*}™¯=™§˜'˜1˜'˜@˜y˜êÓ’»úP˚.˚É6F;ãÛ˜ ˚'˚‚˚˜˜‰˜˜˜-Ù˚˚4˚˚˚b}Œ¯™§˜!˜˜¯0˜psqnR=N‹˜ ∏í˜Ÿö•ÇmUãZ√ì«ãÀ”7∞D-˚"N˚Y˚·!˜⁄Õ≥Ãπ¸ã£˘£Œ˜˜ì£dÅ™®¯‰˚Rsºç\Ä¸ísÄgcs˜É¸ã£¯1£–˜˜ì£dèÉ°™¯˚Ts±ÑöÑ^˚∫[zàgÇs˜ÉÖ¯¸£öõïßØlìyÅxâqt˚˚1√-ã£¯Œg£’˜˜˜∏¯Ø£Zçã™£˜èÿ˜<™T6`Os}â∏”˚Ss≥ÖòÉ^˚∫ZzágÑs˜Ö£]êà®¢ÿ˜üî∂º≥¡åTo˚Üf}zjàs˜¸ã£¯1£÷˜/«˜/˚&˜Ë˜ì£dèÉ°™¯˚Ts±ÑöÑ^˚∫[zàgÇs˜É˚W¯˘`´iπ∂≠¨∑∂iÆ`^jga˚—~˜=˜'˜=›˜=›“\Øfª∫±Øªπe≤\[gc^˜—\Øeª∫±∞ªπe±\[gd^-}Ã¯£Ã˜˜˜¯≠∂^åÄù≤˜¸˚]s≠àßäT˚ØxxrreTä∂ß˜Á˚Ps¥Ñìc˚êD≠FÒŒπ¥§®Jƒûôå˜ò˚*}™¯=™§˜'˜1˜'˜@˜y˜êÓ’»úP˚.˚É6F;ãÛ˜ ˚'˚‚˚˜˜‰˜˜˜-Ù˚˚4˚˚˜Î¯£öõïßØlìyÅxâqt˚˚1√-}´¯%¡˜G£”˜˜7˜'ú˘ ØÑûá\¸Ûó⁄√π^ª™ã˜9œ˜˜˜B˚Fgeyz˜ó˚V˜V˚–°îö∞π‚ë˚P˚1hXOT~æß˚bã£˜ƒ˜%5’s£ﬁ˜ò˜ª£Néö»®˜Q‘∑°ö»´äPã≈Ωô¥•£|¡GJ^Olvâò⁄˚Qs©á£ÜY˚∫YuákÖs˜û˚*ív¯W£˜‚˜+¯y¯a˚+s§ä©ãk~á|ÑzC˚J<˜_Ç¢ãéãè¢üå¨é£˚és§áêãótë©M°U˜˚º•˜4¯ üΩôç£é˚b}”˜O∞˜4™§˜˜8˜Æ˜≠°∞ÆòruëìmãWålÛ˚1txh_P,uÒ‡à˜ê¡à~˜B˚B˚0-˚(˚?ÒA€ƒ´Ë»˜x¨˘¨Æ˜E˜ˆ˜E¯˘&˜ ∞˚D˚&4Ö˚˚?˚?Ö˜‚˜&∞˜D˜ ¨˚U˚5˚˚n˚f˜)˚%˜a˜a˜)˜%˜f˜n˚5˜˚U˜
˜£öõïßØlìyÅxâqt˚˚1√úã§r´˜À©˜•©r§Û˜4˜0˜9˚˜@n˜ú˜Î©uÃà„|˚#N~2˚ayõ∏¯å¢åå•æv‹°PE%ua˚˚å¸	˜÷m˜gè—Ìﬂ˜"Ω7ôçÆµò˜•˜˜0˚`èS˚…rπàµâI¸xNkáSÖ˜ã§˘§˜	˜6˘ï§wå}ç|ù˚≈¯˜<˜@ªºÙë§˚µr”áòÖtxÇÇpp˚m˚n˜j·≠ç¬è§˚Êrπà¥âI¸xNkáTÖr˜Â§Víhè«˜X¶§˜J˚wõxìã~{yàNâr˜‰˚*˚aƒ¯›£õ˜˜S˜+¯t¯a˚+s§ä©ãk|Ü~ÖzG˚TC˜MÇ°Ä•ãï£¶å•ç£˚és§áêãótë©M°U˜˚ªyVÑurOiãÜóêèéêãîùÄ¨^OÖX}k¶]ÃÈ†ƒ˜Ω˜)¯!ûΩúç°é”ív¯W£¯–˜˘W¯a˚sßàüâkuX˚p?âyŸa˜††°ç•ç£˚~s£àñãîvêëwïiG˚?Y˜i◊†•£çôç£˚rs•ÜêÑ•J˜(¸
£˜˜√êÔ˚√¢˜/¯%ú∑ôçûè-}√u¢¯
√˜G£§˜(˜7˜|¯™∂Rçâ®¶¯”˚ks¬á†äV˚K•siØO-(8˚Bº˚&Á7ﬁ÷ßß±ØJ|…úîå˜öº˚ZÁÄfP];ã˜≈ÏôÂ“√°Nä˜x¨˜å§¯¨àw∞˜E˜ø˜0f§Ï˘á˜≥˚Îr–á´âK"`{m3˚QÖ˜ç“˜@≥˜,˜%Í˜ﬂ˚	4Æ§⁄˜~pÍrÅÇvpq>º1˚l˚˚6˚Y˚B˜˚E˜éÏ‚˜ß≠ª˜›£é…íxû˘8ö˚zó˜†í¸ué}ô˘*ô˚vï˜sã˜öì¸|å	∑
˜å
7í	˜é˘
endstream
endobj
15 0 obj
<<
/Flags 262178
/Descent -203
/Type/FontDescriptor
/StemH 0
/CapHeight 676
/StemV 139
/FontName/HOVTWK+Times-Bold
/XHeight 691
/Ascent 676
/FontBBox[-168 -218 1000 935]
/ItalicAngle 0
/FontFile3 14 0 R
>>
endobj
16 0 obj
<<
/Subtype/Type1
/Type/Font
/FirstChar 32
/LastChar 238
/BaseFont/HOVTWK+Times-Bold
/Name/F1
/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 0 0 722 667 722 722 667 611 778 778 389 0 778 667 944 722 778 611 0 722 556 667 722 0 1000 0 722 0 0 0 0 0 0 0 500 556 444 556 444 0 0 0 278 0 0 278 0 556 500 0 0 444 389 0 556 500 722 0 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 389 0 0 0 778]
/FontDescriptor 15 0 R
/Encoding 13 0 R
>>
endobj
17 0 obj
<<
/BaseEncoding/MacRomanEncoding
/Type/Encoding
/Differences[32/space 37/percent 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon 64/at/A/B/C/D/E/F/G/H/I 76/L/M/N/O/P 82/R/S/T/U/V 90/Z 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 135/aacute 142/eacute 146/iacute 150/ntilde/oacute 156/uacute 171/acute 199/guillemotleft/guillemotright 208/endash/emdash 213/quoteright 231/Aacute 238/Oacute]
>>
endobj
18 0 obj
<<
/Subtype/Type1C
/Length 8773
/Length1 8773
>>
stream
  KWTUEF+Times-Roman   @¯ ¯¯¯¯˚<˚n˙|˙
 ãã
 ãã  5  1  ÿª  " ∑¬«003.001Copyright (c) 1985, 1987, 1989, 1990, 1993, 1997, 1998, 1999 Adobe Systems Incorporated.  All Rights Reserved.Times is a trademark of Linotype-Hell AG and/or its subsidiaries.Times RomanTimes  P  . " $ * ´  # 0 & 4    3 / ; ª ' %  F D J C E P        Q U B  ÿ O S M H ” N ) T V W œ ◊ - »  	 
 ! L G ( Y Z I 1 6 5 R } X  [ K  â   7 ﬁ j  x o R   r ‚?u™˙uﬁ·V—2s‡Q≤WÆm˙	B	á	∏	”
<
à
Èíﬂl◊<ÆLxáy÷F˝@Î$^òbÏ:∑H«=≠[—˝ë“EZøDò!¢˛Äï¸$˜Éãû˘û˜∑¯ùÒ˘Û˘*˚[˚q¸ç˚{¯ç˚Zx’á†É=¸*˚ v|?Üx˜ûBév°Ú¯#ç˜ç¸∂ô˜í¯Õç¸U9~|=áx˜¨ûKètîÿ¯P⁄£ë ê”ãû˜Y¥¯5wö˜˚˘GË˘Vû_é}ñk‘˚ç¯Ãw˚d¸x_lBtryxzâ{äx˜Zûv\ãµñéôêòπ˜	˜ö¥+ë}òjã{fjäfx˜ì¸~˜ï˜˜ß˜˚ßú}∑¯Ú≥ß˜˘ ¯WÇ˜uvjÉjãÜuJ¨2˚@˚<˚˚t˚ç˜A+˜5˜L·˜çåyùlmCD˚ã˚˚‚˜h˜$∑À≤±¥µ≈üΩ˜”;"§˚—ãû˘û˜Òù˜ΩûAçsïŸ¯P€§í‘éû˚ΩxﬁáôA¸PDz6â”ãû˜Y¥¯5wö˜˚˘GË˘Vû_é}ñk‘˚ç¯Ãw˚d¸x_lBtryxzâ{äx˜Zûv\ãµñéôêòπ˜	˜ö¥+ë}òjã{fjäfx˜ì¸~˜ï˜˜ß˜˚ß˚¯b˜.Ïïëüòã¢èäßk}Ñãtt˚'˚(˚—†v˜V ≤˜ä≤˜ïL˜ä úãûx∞˜µ≥˜ó∞xû˜Ò˜ÜÒ:˜Æú˘›áôA¸PDz7âx˜‚≠˜rü˜±Ù;ª4ùçÆ∏ñ„°˜˜/˚Cô4˚¨˜Z˚‰Î´ÜÅ≠uø{ºj9˚˚ÇIQyè∞¯ôöçôüïôåã†∂“Ûx˚˚˚âo,ä”}Ø¯˛Ø≠˜¯>˜˜˝}˜I˜&˜˜i˜z˚7˜˚8˚8˚7˚˚z˚i˜&˚˜IØ˚%‰˜p˜x˜‹ÒÒ˜:˚x˚p%2˚dã±˜µ¥˜î±xûÓÒ˜ú¢¨ˇ Ä Ó¯È˜=o&_Ym˚˚)ãå¥˜å˜.âﬁäö}ó;¢˜|tDÄÅs2˚.˜r≠óã†˜˜•{2ö§à˜#¸ßﬁx Ü£Ö<¸P>tÇKáx¯∞-}Ø¯˘¥“·˜}¯S˘8vÄâÜtorU≠O10S˚(À_ÁV˜'5õiRUcR;˚X˜∫xt©˚h°õïú†©ºiã◊˜#œÎ‡˜a˚‚üã˜*…æ™ΩÙÀ19ú§¸$˚*ãö˘)w˜i·˜
˜®ö@wñª¯ÏÉç˚H0}°√ããó≠ãqv¸YAfâQâ¸$Ö˜ 8v˜0≤†ﬁ˚!©ï›Õ“ﬁQòtrj|`cØÅ•íêååéåèéåç`ííÜÇx{^Iaúãû˜¥Ø˜Æ∞xûÒÒ˜~˜Ï˘'ûbçsùu¶˚b˜ëæï˜£˜˜.˚9†2˚®‹x—ÑöÇA¸E@áv:Üx˜©û;èÅûŒ˜Y√ç˜Ç˚»˜5Ï¸[¯·®îí¿¥˜à˚˚#˚*â7ä”ïvñû˘û˜∑¯3∑x˘W˘*˚xœÜßÉ˚˚‚â¸¯u˚?x≥õÜY¥¸M˚ v|?Üx˜ûBév°Ú¯ç∏¯L¸∏ú¯¢˜	´è ídã±¯ﬁ±î¯‡¯“˜DBuxJ˚˚ï¯D¯ıö¸¢w˚?•ŒòóÕ˜#˜q¸I¸ı|¯»£˜D”}Ø¯˛Ø≠˜¯>˜˜˝}˜I˜&˜˜i˜z˚7˜˚8˚8˚7˚˚z˚i˜&˚˜IØ˚%‰˜p˜x˜‹ÒÒ˜:˚x˚p%2˚j˘M˜.Ïïëüòã¢èäßk}Ñãtt˚'˚(-ãû˜»¥˜î±xûÓÒ˜ì¢µˇ Ä Ó¯s˜{˜|t@Åyw9˚%˜r©íè§˜˜•{2ö§à˜#¸ßﬁx Ü£Ö<¸E9|@áx˜¨ûDéwó÷˜n˜%÷â£Åñ7”ã∞¯‡∞xûÛÒ¯˜ÿõ˜∞˜∆⁄˜X˜˜t˚3˜˚Ñ˚¢∏xÿÖñÅA¸PE{?áÿ˜R¯Àüãû∫˜√p`ª–M£:7˚∑˚äãK[í≠˚*ã◊¯¢’˜Ê·¯o˜~êdLxàfã˚É˜<˜D∑∫ﬂÊãı˜1œ03-[˚+m†Ü°¡©◊Êã˜
§/X@`14.˚F˚Q¯˚bÅ–˜n´˜Ø§–˜eÒ¯,˜8ft`G2I:¥˜E˜À˜ÄDø-;˚N˚M˚"◊9˜˜$≈˜™ï˚€˜,„õ≤¶¬⁄ïH[í˚bÅ”¯®§ÿ¯"˜0Xif`C7F◊˜˜'Á™∞¿êymìëuëvõr£ãé©çõû¢ù~™m†õr^ög˚ ˚8˚8˚2ˆJ€‹Ã∂˜¡¸ãö¯ñøw¢w˜!ÒŸÒ6ﬂ⁄õ˜ÅöFèÜúÕÍ˜˜áéWxXxWz|çòòçôõûäP˚|=zÖMà‹…¯˝xôkØ©°°®ßu¢mh|kx˚*Å´¯ ˜8ö∑w–ﬂ˜w„˜-˜÷ƒèÀù´ÊØ$.I{˚˚rDòÆ7{fÙpΩ˜M∆˜2ÂˆR˜˚?VQtÖâ˜¬Üç[zZ}[~{åëïãë∑ãvm˚*Åøovºö¯ß˜8ö∑w¶·˜wﬂü˜ËÒgÉdsaIC√˜)˜œº√∫ºkGí?˜+˚¶äÑÖãÜZãü∞¯ÀÜç[zZ}Y~{åìïãë∑ãvm˚0®jmô`˚,˚˚ü˚`˜#w≤’∞∞¶ùçNèà¿ûπõªú˚*Åß¯2ß®Â˜ôÂ˜â¯`˚9˚˚˚Â$˜˜,—˜Ó˜%-‚˚ú¸N˚t˜L’Û¬ø Áæ˚˚˚#HeX¸ïvã˜˜å˜ãw‹˜®˜˜†Æú∞™q•mmrrke≠{†˚˚†Æú∞X™q•mmrrk®e≠{†˚*òv¯Ë’ü¯A¯U˘*¸{_`$úÉ¨øù®Ãã˜m˚Z¸ËÃ˜h˘"¸ív˘FwÇ˜º˜≥˘8H˚y˝Fœ˚*}∞¯ƒ⁄˜¯—˜I¯€˜Xñîãîé±‰ÇíÄ|ÇÄqã˚e˚˚ÅäâãâãäÜéàè˜ á˜E\˚4˚ASJUp…ãKcãnÅg∫s⁄˜2˜ı˜‰Ä®`øP”-ú;ô˚*}•˘•£Î˜òÎ˜é˘˜ç˚èG<â˚Ñ˚˚â˜Ç‹œç˜è˜•˚La˚w˚
˚µ˚t˜L˜Lµ˜t˜˜
a˜w˚L˚*}ß¯π˜Ñõ≠Ë˜èÂ¯R˘@˚ÜÉ˚>˚J˚_˚fÒ,˜
˜FØ˜3‘˜=◊!SvjTû˜Ó˜˜Fß˚b˚≤ı©'$˚]WL@H’˜<«ï£ïï£§Øì≠¸$ïvã˜—˜†˜Ä†Æú∞`™q•mmrrk†e≠{†˚*˚mù˜Q´¯öÇ«÷ﬂ˜u·‹÷˚`ávIÜz˜ÜùC{ñÀ˜1k¨ßÄ≥˜“˜ ˜˜?›2>]Zovâç‘ÖçÏ[x[z[|{åîïãîÆézc‹ﬂà±ë√ßØ˜ê˚6t˚B1xjT\∂¢¸Åø¯´—ﬂ˜ì¯V&˜ìãêÑfV|ueduuuÖããàçàçä¿˚¡'¥pæπ∫¨∂£~ñÄ~yukãXã∆™˜≤˚bÅƒ˜Üv˜<£∞„Fﬁ˜(‹Ù˜≥˜màl|ÜÇl~ufn™∫ç≠ñ√˜+Ω˜/˚^ÇÄ~Åvnã®®˜W«ãÔ˚)Ï˚\Dc{óo™•û°†îÜöãö™±ù¨©∫ÄCNÙ˚7K4i'Høf¡¬¿≥¨∞Cêµäùõ™åºµ˚*}Ø¯Ê«˜“⁄e”–˜-˜ﬁ§æ¢Ö{™ÀjóAr@b<.Pe√ã]{tÑoW‚Ü£˜1˜„˜"˜6Æaù‡Õ∂¶∂¡¥pÈ˚H2l˚cöáößµŸÊã’ØVX/@[0n˚*Åß¯2ß®Â˜ôÂ˜â¯`˚9˚˚˚Â$˜˜,—˜Ó˜%-‚˚ú¸N˚t˜L’Û¬ø Áæ˚˚˚#HeX^¯}˜.Ïïëüòã¢èäßk}Ñãtt˚'˚(˚*ãö¯òÅ¬€ﬂ˜Dﬂ∏€ÂP|~\à|˜höWé}õ¨˜≠∞±™ü©∆ùgN˚e?qÜfà|˜döZèö∫˜y˜D¶]Peh]Z⁄Ñçÿ]z\|^~zçèñçôõûäL˚—ãö˜ÔÌIóÇ ◊ﬂ»◊ﬂS{àTÅ|˜ÑöXçiè–ò˜u´∑Ω£»£ïhãÆ£ôû§¨w†ieiwD\â‰Üç®ZwYyZ{{çîñçôõûäP¸ãö¯ˆô∑wÌﬂ†˜ÄöQézì≈¯ÈáçVzV}V~{åóîåò≤ë{^¸qTy~Pá˚*˚nƒ˜Hv£v˜(§˜j≤êßß—nﬁ<«˜Xÿ¶ß÷ Ì1©ù†™∞∫Å°ãÈà’âºâã^ãVG_˚	ã˚ãg≥ã™µ`¡¯DŒ≤¢Ø·õ˚ouÜAG=q‰⁄π ˜“π≤>{yçìvµ öcuìh?+[˚Q≠]∆q¥†2<ã~zo•¶~∂ Xg\b^V÷_ÒÂ˜:√˜ß}’ ê∏‡˚ëmå[éã¢ü≥¥üçëØÜãó√Ú≤˜ ΩÇûÅ¢¸ãö¯ñøw¢wÍﬂÿõ˜ÅöFèÜúÕË˜˜áé˚/T|çòòçôõûäP˚|=zÖMàÂ¯Ä˜.Ïïëüòã¢èäßk}Ñãtt˚'˚(˜ãö¯òÑø·ﬂ˜Lﬂ˜Lﬂº·‡Hmâcä|˜röhåjçº˜Æêπ¡–øúdI˚mJtà^à|˜töbålé◊˜ê≠°≠¶¬”åPX˚gK{âYÖ|˜oöqçaíä¶ã°˜e’}Û#<NOsvµÄlµJUbk^P÷Ñç‹]z\|\~zçìïçôõûäL”ãû˜º∑˜∞ûˆÒ˜√Òû˜™û=êÅûÕ˜b˜√˚W@áu7áx˜™û=êÅûÕ¯P“óò◊ëû˚™x’ÖôÅA˚V˚√˜V“óò◊ëû˚™x’ÖôÅA¸E@áu7á˚ôÅ°êv¯[wë¢æ…Nò˜i—[ò•˜œ˜Œá˜ÄôáàÜÑÇzlü_*`ISA¬f…hñ≈j´yüsãkR\{i)x‚¿{U˚0òñîëèéóçßµyã∑À‹µ‚«hßZ©ô˚ Àf°Ö®ãü•†≤¬∑∏v%°˚*Å≈iv∂ô¯ú“ﬂ˜Fﬂ<¯sΩÑVâ°Æ˜Î˚2z—âèvcú˚jÑÅÇÉupm}mIÇ…ô˜⁄˚&}©â´âO˚ê!Ÿs¥ùªè≤≤|∂∂8çâ∫ú±ô¡ô˚*ív¯Uö¯Á¯q¯V˚|§ä°ÇtgD˚0i+%˜îàìÖöãó§°é£çö˚X|üäüÖömØDÎ˚|£Mõ`çáîãíãî¢ñ¶˜˜’£∆íõ≠é˚bÅ–˜n´˜Ø§–˜eÒ¯,˜8ft`G2I:¥˜E˜À˜ÄDø-;˚N˚M˚"◊9˜˜$≈˜™ï˚€˜,„õ≤¶¬⁄ïH[íA˜Z˜.Ïïëüòã¢èäßk}Ñãtt˚'˚(˚*ãö¯òÅ¬”√Å¬€ﬂ˜Dﬂ∂€ÂP|~\à|˜höWé}õ¨˜≠∞±™ü©∆ùgN˚e?qÜfà|˜döZèö∫˜y˜D¶]Peh]Z⁄Ñç÷]z\|^~zçèñçôõûäL˜∆˜¿cz}Åp|vîëÆsótóuëvãHmR_É®úëñ®±óòÜÖó∂¢Ä®}†Å™ãŸù”≠îdã≤¯ûÓÒ˜∫˘*˚Æx Ü£Ö<¸P>tÇKáx¯Æª˜Br˚RKá˚*8yå≥¯m⁄§íœè˚bÅƒ˜Üv˜<£∞„Fﬁ˜(‹Ù˜≥˜màl|ÜÇl~ufn™∫ç≠ñ√˜+Ω˜/˚^ÇÄ~Åvnã®®˜W«ãÔ˚)Ï˚\Dc{óo™•û°†îÜöãö™±ù¨©∫ÄCNÙ˚7K4i'Høf¡¬¿≥¨∞Cêµäùõ™åºµ˚ë¯g˜.Ïïëüòã¢èäßk}Ñãtt˚'˚(˚*†v˜;À¯Qwó≥˜ÑŸ¯l˜{%¯Q_˚Œ¸QK˜≠˚;ÿ˜;Ò˚HÀ˚Ñ˜Ç˜Ëç˚—†v˘8wª·˜ª˘8˚///˚*˚@˚¨CºC±SÕE≈lóõ˚>˜ã˜oÒ˜íÎŸ’∆˚—†v˘8w˜[·±˚E˜/ÁÁ˜*˜@˜j”Z”e√I—Q™{˜>˚ã˚o%˚í+=AP˜£}≤˜
¨k∂˜©∑˜™˜ﬂ˜“˜"Œ˜<≥æÄ¯–¯#˚!~MDaho£«˜‰”ªﬁÄ©òta˜˚⁄qRWu2˚B˚˜˜#˜r˜˜
˜-˜KÙ˚+˚5Z˚
:ﬂÄkÖ£üìåìåèÃ˜íFÅe~£ß]ã˚M˚>EæÄ˚ |©éﬂÄ≈ëππñùçä}£SÃ˜Œ˜Ò˜=˚$˜˚L˚Z˚;˚%˚l˚˜˚W˜ôŸœß® ˚*ãö¯8ö˜Cô∑w›ﬂí˜~öwåjçuìã¥˜Iç˜˚LózîÇãÑ~~àÉx|˜nöpçdíXÀ˚-˜V®¶˜˜ßã¿ãö˚`}µìÉÄÇÉÄ|}ciPTglâç¯4áçVzV}Z~{åìîåò≤ë{^¸vUÉâHÄ˚—ãö¯'´˜aßÚﬂ˜…¯V˚˜∞êø¬∫ê@ãµü¢ò®≠_¶S˚Hã˚ES9k›˚Œ>zÇIà|˜òö/çä•»˜Œ˜”}≥˜ ù˜Æ≥´˜¯ Ïd•¯˘Y˜ˆ˚ìyœÜüä8˚6gFtG˚/#˜˜I˜ë˜' ÍÙ˜ ø(C¶¢É˜guoÖjÜÉk]¨&˚h˚˚;˚<˚©P¿Q>“˜mÓ¯˜˜≈ô˜]“•ç∑è˚*ãö˜©v˜8öú˜%˚%¯b˚`˜2Ë˜¬‘èÜó|vÇálä|˜]özåpåe≈˚˜XÙﬁ˜ìò©©∂åö˚2|úä¢ävÄÖÇN3x®b»ù†§çùö˚c|ï•ôÖUØÈ˚$˚˚9k]}âpà|˜%özvãùâñô†ëî⁄˜˚*˚nﬂ7Ò¯ªöô¯a˚˜®¯o¯V˚|è®öÅyÇ~kÅp=˚r˚˜ëàíÑõãò¶Æå¢åö˚b}òâ•Üór˜˚äôlª/|{c˚Wp~lùãp]âeÖ®q¢kΩ÷∑Õ˜æ˜.¯,ö¥üçòç˚*ãö¯¡˜8ö∑w‘ﬂ˜Nﬂ¯{öYîÅê‘˜[≥ä˜˚OZkYhâ˜¬Üé[zZ}^~{åéïãë∑ãvm¸kBÅÑUÑ|˜löZêxêÿ˜Öª¥≤ö®¬°dH˚Z>xÜZÜ|˜h-ãû˜°≥˜Ω∞xûÔÒ˜{˜‹õ˘‘ÑñD¸ECãt7Öx˜¨û>çzö‘˜Jâ£ûä£ÙÀù¥∂úõ∑¥ŸÏ˜˚¿˚˚ú˜ND¨ñå©∑˜&â˚#˚,˚ãfvwåçx”}∑¯˘ûÛÒ˜˝∑˘U˘*˚|x—á£z ˚¢:Åj~u\nRk=˚Bã˜À˜‘“óò⁄ëû˚Øx◊ÜôÄA˚ÃOã˚W˜å˜óã˜P€˜ôÙúöÿìdãû¯Ìµ¥v˜~Ò˜~v8¯Xû7éûœ¯ì¡˜ßy˚†£Ö˜>¸»Ö˚>£˜°¶û˜¡¸àAàt0áx˜∏˚*˚mú˜R»¯ßáw£·˜{ﬂÏ˜¸¯=°dtòX˚)˚˚˚+÷D‰»—µ©úê˚NY}t@àz˜Äô^ïyèª‹¯ÈáèÑàB˚ﬁäkã{WxyÑzâ|ã2ãdÍãÁÏ˜¡‘‹ÍåDo˚—†v¯è˜?Ë˜t˜¯è˜.Ïïëüòã¢èäßk}Ñãtt˚'˚(”ív˜¿v˜>ö†˜¯4˜¯œ¯V|£ÜüásÖpÄr1˚r;˜j|≤Öñãù®§é¨êö˚_|¥ÜñÑ∞˚0˚[]˜P˜Æß¢è¢çö˚H|§âì~ü[˜˚ÍiôêÅíëêñßô˜˜ÑÊ˚ÄôgçÑìãìèï≤õ˜˜Óö∞êï†íö˚—†v¯Ã˜ ãw˜G≤∞ı¯E©ï›Õ“ﬁQòtrj|`–cØÅ•íêååéåèéåçííÜÇx{^Ia˚bã©¯©ˇ 6Ä ˇ Ä ¯6˜yè{=Öl!ã˚˜°¯)ö˚Ôà˚
ù¡íè≠‘˜˚û¸)|¯¸˚n≠¯÷óæw¢w˜!ÒÁÒ6ﬂ⁄˜^9ãRYgÅ«ã`xv|tfπx∫˜¥˜	Í¯]ÜéWwWyW{{çöòçôõûäP‹z˜æxôkØ©°°®ßu¢mh|kx˜Kìvò©˜ó≠õ´˜h§£©ôw»◊˜r§Ã◊˜q•U‡˘+¯˚#˚!F©GË˜⁄˜*˜ÚBígU‡òk≥©gZ6E˚4Kã√üµ¡˜SÏ[‡a˜Âdmkbe7Wyôò{u‡ô{}ò]˚
*˚'&”h∏˜ÿ˜/Ûù‡†àïáôÖöóá≤¡ßöò¢çâ˚Ò˝ªu‡Y˜‰dtû¬ﬁŸ˜,Õû~{{ ëxéÄz˚;˚
;˜Ú†v˜]ºã˙|˜éZ˙|º˚*ûv˜É∂¯ß©Á˜ÑÏ∆u˜íõ˜&˜R˜h˜;+˜˚˚;˚ ˚9π˚˜Ω¿ù∞∑çâÖrT˚w˚Üc˜∆˜˘yà~Åzvayj!u˜	◊›¢Ëﬂ˜ã˚WP˚*}ß˘ß√◊E’˜o–T◊‰˜h˜Ã˜9µmAE\aL:]ÃÿËÊª≤´•˚0˚:=Õ9˜‰˜:¨˜øŒv≈˚Îÿ¡®€µÁ◊MÕ˚5&U&:≥iﬂAË2Gbl4ÿ€¯%ª´¿÷ÿÆUT3Sferg¢2ƒŸ”ïv˘"û¯…˜˘M˘*˚ax±âÆàbvzaâÖ˚'¸˚+˜Êtæy¥ãö´ûç√éû˚ûx∫âù¥0˜ä¸πö˜r¯≈©◊ôôªé˚*Å≈iv∂ô¯ú“ﬂ˜Fﬂ<¯sΩÑVâ°Æ˜Î˚2z—âèvcú˚jÑÅÇÉupm}mIÇ…ô˜⁄˚&}©â´âO˚ê!Ÿs¥ùªè≤≤|∂∂8çâ∫ú±ô¡ô˚ö¯k˜.Ïïëüòã¢èäßk}Ñãtt˚'˚(˚*¡v¯wµ¯2µ˜wâ’KïÇSÀ¬Lìëêèíòo≥y£u©d∑u©°®ı˜ãôãíâèÉãáãããKLHPjo˜5pâ’KïÇSÀ¬Lìëêèíòo≥y£u©d∑u©°®ı˜ãôãíâèÉãáãããKLHPjo¸Ö˜ 8v˜Ú˜ãw‹˜≤îˆ˚!¨ó⁄Ã—ﬂPóvÄ[àTf©~´íêååéåèéåçTííÜÇx{^Iah±¯j†Æú∞™q•mmrrke≠{†˚*¡v¯w∑¯2¯^˜rçAÀÅî√KT ÉÖÜáÑ~ßcùs°m≤_°mun!˚ã}ãÑçáìãèãããóóÀ Œ∆¨ß˚5¶çAÀÅî√KT ÉÖÜáÑ~ßcùs°m≤_°mun!˚ã}ãÑçáìãèãããóóÀ Œ∆¨ß˚*†v˜]ºã¯à˜éZ¯àº}ô˘*ô˚vï˜sã˜öì¸|å}ô˘*ô˚vï˜sã˜öì¸|å	ß
ﬂ˜é˘
endstream
endobj
19 0 obj
<<
/Flags 34
/Descent -217
/Type/FontDescriptor
/StemH 0
/CapHeight 662
/StemV 84
/FontName/KWTUEF+Times-Roman
/XHeight 676
/Ascent 683
/FontBBox[-168 -218 1000 898]
/ItalicAngle 0
/FontFile3 18 0 R
>>
endobj
20 0 obj
<<
/Subtype/Type1
/Type/Font
/FirstChar 32
/LastChar 238
/BaseFont/KWTUEF+Times-Roman
/Name/F2
/Widths[250 0 0 0 0 833 0 0 333 333 0 0 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 0 0 0 0 921 722 667 667 722 611 556 722 722 333 0 0 611 889 722 722 556 0 667 556 611 722 722 0 0 0 611 0 0 0 0 0 0 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 0 0 0 0 0 0 0 0 0 0 0 0 444 0 0 0 0 0 0 444 0 0 0 278 0 0 0 500 500 0 0 0 0 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 500 0 0 0 0 0 0 0 500 1000 0 0 0 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 0 0 0 0 0 722]
/FontDescriptor 19 0 R
/Encoding 17 0 R
>>
endobj
21 0 obj
<<
/Type/Pages
/Kids[22 0 R 23 0 R 24 0 R]
/Count 3
>>
endobj
22 0 obj
<<
/Contents 5 0 R
/Type/Page
/Parent 21 0 R
/Resources<</ProcSet[/PDF/Text]/Font<</F1 16 0 R/F2 20 0 R/F0 12 0 R>>/ExtGState<</GS0 1 0 R/GS2 3 0 R/GS3 4 0 R/GS1 2 0 R>>>>
/MediaBox[0 0 501.73199 700.15698]
>>
endobj
23 0 obj
<<
/Contents 6 0 R
/Type/Page
/Parent 21 0 R
/Resources<</ProcSet[/PDF/Text]/Font<</F1 16 0 R/F2 20 0 R>>/ExtGState<</GS0 1 0 R/GS2 3 0 R/GS3 4 0 R/GS1 2 0 R>>>>
/MediaBox[0 0 501.73199 700.15698]
>>
endobj
24 0 obj
<<
/Contents 7 0 R
/Type/Page
/Parent 21 0 R
/Resources<</ProcSet[/PDF/Text]/Font<</F1 16 0 R/F0 12 0 R/F2 20 0 R>>/ExtGState<</GS0 1 0 R/GS2 3 0 R/GS3 4 0 R/GS1 2 0 R>>>>
/MediaBox[0 0 501.73199 700.15698]
>>
endobj
25 0 obj
<<
/Type/Catalog
/Pages 21 0 R
/PageLabels 8 0 R
>>
endobj
26 0 obj
<<
/XPressPrivate(%%DocumentProcessColors: Black\n%%EndComments)
/Producer(QuarkXPress(tm) 6.5)
/CreationDate(20071120115332)
/Creator(QuarkXPress(tm) 6.5)
>>
endobj
xref
0 27
0000000000 65535 f 
0000000015 00000 n 
0000000059 00000 n 
0000000111 00000 n 
0000000157 00000 n 
0000000204 00000 n 
0000007777 00000 n 
0000017156 00000 n 
0000021290 00000 n 
0000021335 00000 n 
0000021732 00000 n 
0000030054 00000 n 
0000030277 00000 n 
0000030862 00000 n 
0000031120 00000 n 
0000035844 00000 n 
0000036066 00000 n 
0000036727 00000 n 
0000037218 00000 n 
0000046074 00000 n 
0000046292 00000 n 
0000047032 00000 n 
0000047103 00000 n 
0000047329 00000 n 
0000047545 00000 n 
0000047771 00000 n 
0000047839 00000 n 
trailer
<<
/Size 27
/Root 25 0 R
/Info 26 0 R
/ID[<F5EE80B21F5486CFAF1EE26E227B676B><F5EE80B21F5486CFAF1EE26E227B676B>]
>>
startxref
48014
%%EOF
